Netabolics | AI-Driven Biosimulation

We use virtual human cells
to understand diseases

Our AI-driven biosimulation platform provides unprecedented decision analytics to de-risk drug discovery

OUR LATEST MODEL FEATURES

Genes

0 K

Molecular Species (Proteins & Metabolites)

0 K

Gene-Associated Chemical Reactions

0 K

COMPANY

Netabolics Predictive Biosimulation

Netabolics is an award-winning AI-driven biotech startup based in Rome, Italy. The company works to bring disruptive innovations in the pharmaceutical R&D processes. Our team includes life scientists and software engineers working collaboratively to produce the best genome-scale simulation of cellular biology for in silico drug target selection.

Our discovery platform predicts the many thousands biological changes occurring inside any cell type in response to pharmacological, genetic and environmental factors — in seconds. Predictions do not have to be perfect, but they need to inform decision-making in drug discovery, because quicker Go/No-Go decisions accelerate the progress towards safe and effective medicines for patients.

Mauro DiNuzzo, Founder & CEO

At Netabolics, we envision a future where drug discovery is transformed through the power of AI and biosimulation. Imagine a world where you can simply specify the desired outcome, such as a healthy cellular phenotype, and let our technology identify the most promising biological target, or combination thereof, for advancing drug discovery programs.

Our mission is to accelerate the development of new medicines that make an impact on people.

We have an international network of academic, industrial, and technological partners, collaborating research laboratories, and customers that trust our technology.

We constantly seek mission-aligned partners to advance our discovery platform.

TECHNOLOGY

Where AI Meets Biosimulation

Our patented technology couples ordinary differential equations (ODEs) with deep reinforcement learning (DRL) overlaid onto first principles of physics and biology to automate networks/systems biology and pharmacology model simulations and empower drug discovery project teams to identify and validate biological targets of diseases and disease biomarkers.

By leveraging artificial intelligence, publicly available knowledge base, and internal databases, our proprietary algorithms create mechanistic dynamical systems starting from digital reconstructions of human cells for simulating cellular biology and predicting the effect of new drugs.

Our approach to in silico drug target selection using AI and biosimulation.

Outcome-Driven

We believe in using simulations to guide the drug discovery process. Instead of navigating through complex pathways and countless potential biological targets, we focus on the desired outcome. Whether it’s targeting specific cellular functions or achieving a particular therapeutic effect, we just set the goal and our technology handles the rest.

Customized

Every project is unique, and so are its specific endpoints. We tailor simulations to our specific requirements, ensuring a precision path to drug discovery. Our solution is fully customizable and it can predict whether a target is disease-associated or it is disease-modifying by simulating how both healthy and diseased cells respond to perturbations.

Cutting-Edge

Our platform utilizes state-of-the-art biosimulation and AI/ML models to simulate and analyze biological networks. By leveraging advanced deep reinforcememt learning (DRL) algorithms, we identify efficacy and toxicity biomarkers as well as the optimal biological targets that align with our defined outcome for both mono- and combination therapies.

PLATFORM

In Silico Drug Target Selection

Our platform integrates the predictive power of AI/ML with the explainable and deterministic nature of ordinary differential equation (ODE)-based biosimulation. Applications include what-if scenario analysis to validate known biological targets, and target deconvolution analysis to discover novel biological targets.

We employ our platform to identify and validate the biological targets of disease, predict the biological effects of new drugs, and optimize their efficacy and toxicity profile, with substantial time and cost savings.

Here we show our predictive analytics on a model system of pan-cancer metabolism.

Our proprietary biosimulation algorithms are rooted in biochemistry and are incorporated in a suite of powerful computational tools that ensure full compliance with real-life data across the entire modeling framework.

Mauro DiNuzzo. How artificial intelligence enables modeling and simulation of biological networks to accelerate drug discovery. Frontiers in Drug Discovery, Section In silico Methods and Artificial Intelligence for Drug Discovery, Volume 2 (2022). https://doi.org/10.3389/fddsv.2022.1019706

Mauro DiNuzzo, Alessandro Scandurra, Marco Salvatore. Biosimulation-based target deconvolution of cancer metabolism. RExPO24 Conference, 3 (2024). https://doi.org/10.58647/REXPO.24000057.v1

PIPELINE

Combinational drug discovery & repurposing

The following table provides an overview of our early-stage development programs.

THERAPEUTIC AREA

TARGET

DISCOVERY

OPTIMIZATION

IND-ENABLING

CLINICAL

Oncology

Multiple Targets

Our pipeline is powered by in silico research and development capabilities. We are focused on discovering new combinations of repurposed drugs for oncology. We actively explore partnerships for co-development.

Not sure about our discovery platform? Don't trust us. Request a demo.

Ready to see how AI-powered simulations can revolutionize drug discovery? Contact us today.

First Name

Last Name

Organization Name

Request

GDPR

By sending this request, I confirm that I have read the Privacy Policy and GDPR Information (art. 13 D.Lgs 196/2003; artt. 13 and 14 EU 679/2016) and accept the relevant terms.

* Required fields

Netabolics received funding from the European Regional Development Fund Pre-Seed Regione Lazio POR-FESR 2014-2020. The aim of the Pre-Seed grant (Prot. n. A0122-2020-34411 - 10/03/2020) is to support the development of the proprietary cloud platform of the company (as academic spin-off) and the consolidation of the business idea to make it ready for the market.

Netabolics received funding from the European Regional Development Fund Voucher Internazionalizzazione Regione Lazio POR-FESR 2021-2027. The aim of the projects (Prot. n. A0655-2023-080608 - 10/12/2023; Prot. n. A0828-2024-089363 - 14/01/2025) is to support the participation of the company to the following international events: BioTechX Europe (Basel, Switzerland, 9-10 October 2024 and 6-8 October 2025), Festival of Biologics (Basel, Switzerland, 15-17 October 2024 and 30 September-2 October 2025), Welfair (Rome, Italy, 5-7 November 2024), AI-Driven Drug Discovery Summit (Boston, USA, 12-14 November 2024), World Orphan Drug Congress (Amsterdam, The Netherlands, 28-29 October 2025).

Netabolics is a proud associate member of the network.

Netabolics is a research focused deep tech-based biotechnology company. Our mission is to leverage genome scale biosimulation and AI to understand disease biology and discover novel therapeutics.

COOKIE POLICY PRIVACY POLICY TERMS OF USE

Via Cristoforo Colombo 456
00145 Rome, Italy

We use virtual human cellsto understand diseases